1 Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl 2016;387:1540–50. doi:10.1016/S0140-6736(15)01281-7
2 Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395–408. doi:10.1016/S1470-2045(19)30407-3
3 Takada K, Toyokawa G, Shoji F, et al. The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Clin Lung Cancer 2018;19:120–9. doi:10.1016/j.cllc.2017.10.014
4 Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11. doi:10.1038/s12276-018-0191-1
5 Jardim DL, de Melo Gagliato D, Giles FJ, et al. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res 2018;24:1785–94. doi:10.1158/1078-0432.CCR-17-1970
6 Chen TW, Razak AR, Bedard PL, et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol Off J Eur Soc Med Oncol 2015;26:1824–9. doi:10.1093/annonc/mdv182
7 Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017;28:2377–85. doi:10.1093/annonc/mdx286
8 Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Published Online First: March 2017. doi:10.1200/jco.2015.66.1389
9 Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 2018;36:638–46. doi:10.1007/s10637-017-0534-0
10 Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278. doi:10.1136/esmoopen-2017-000278
11 Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol 2018;4:374–8. doi:10.1001/jamaoncol.2017.2925
12 Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 2019;17:1464–72. doi:10.6004/jnccn.2019.0059
13 Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2018;29:iv192–237. doi:10.1093/annonc/mdy275
14 Humbert O, Cadour N, Paquet M, et al. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging 2020;47:1158–67. doi:10.1007/s00259-019-04573-4
15 Rossi G, Bauckneht M, Genova C, et al. Comparison Between 18F-FDG PET–Based and CT-Based Criteria in Non–Small Cell Lung Cancer Patients Treated with Nivolumab. J Nucl Med 2020;61:990–8. doi:10.2967/jnumed.119.233056
16 Goldfarb L, Duchemann B, Chouahnia K, et al. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res 2019;9:8. doi:10.1186/s13550-019-0473-1
17 Tsai KK, Pampaloni MH, Hope C, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer 2016;4:58. doi:10.1186/s40425-016-0162-9
18 Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143–52. doi:10.1016/S1470-2045(17)30074-8
19 Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med Off Publ Soc Nucl Med 2009;50 Suppl 1:122S-50S. doi:10.2967/jnumed.108.057307
20 GRAMBSCH PM, THERNEAU TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515–26. doi:10.1093/biomet/81.3.515
21 Marandino L, Capozza A, Bandini M, et al. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. Eur Urol Focus Published Online First: 7 November 2020. doi:10.1016/j.euf.2020.10.003
22 Mekki A, Dercle L, Lichtenstein P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer Oxf Engl 1990 2018;96:91–104. doi:10.1016/j.ejca.2018.03.006
23 Xu C, Chen Y-P, Du X-J, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;:k4226. doi:10.1136/bmj.k4226
24 Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–80. doi:10.1038/s41571-019-0218-0
25 Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30. doi:10.1056/NEJMoa1412082
26 Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res 2017;69:1751–63. doi:10.1002/acr.23177
27 Maillet D, Corbaux P, Stelmes J-J, et al. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer Oxf Engl 1990 2020;132:61–70. doi:10.1016/j.ejca.2020.03.017
28 Grangeon M, Tomasini P, Chaleat S, et al. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer 2019;20:201–7. doi:10.1016/j.cllc.2018.10.002
29 Toi Y, Sugawara S, Kawashima Y, et al. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. The Oncologist 2018;23:1358–65. doi:https://doi.org/10.1634/theoncologist.2017-0384
30 Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019;145:479–85. doi:10.1007/s00432-018-2805-3
31 Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018;115:71–4. doi:10.1016/j.lungcan.2017.11.019
32 Sachpekidis C, Kopp-Schneider A, Pan L, et al. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging Published Online First: 18 December 2020. doi:10.1007/s00259-020-05137-7
33 Humbert O, Chardin D. Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. Front Oncol 2020;10:566297. doi:10.3389/fonc.2020.566297
34 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis – What to do and when? Best Pract Res Clin Gastroenterol 2020;48–49:101703. doi:10.1016/j.bpg.2020.101703
35 Kobayashi M, Yamaguchi O, Nagata K, et al. Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc 2017;86:915–6. doi:10.1016/j.gie.2017.04.033
36 Boike J, Dejulio T. Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J 2017;4:e57. doi:10.14309/crj.2017.57
37 Cheung V, Gupta T, Ye W, et al. PTU-061 Immunotherapy-related gastritis in a tertiary oncology centre. Gut 2019;68:A147–A147. doi:10.1136/gutjnl-2019-BSGAbstracts.277
38 Gandy N, Arshad MA, Wallitt KL, et al. Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging. Br J Radiol 2020;93:20190832. doi:10.1259/bjr.20190832
39 Frankel AE, Deshmukh S, Reddy A, et al. Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. Integr Cancer Ther 2019;18:1534735419846379. doi:10.1177/1534735419846379
40 Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 2017;28:1368–79. doi:10.1093/annonc/mdx108
41 Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103. doi:10.1126/science.aan4236
42 Conti L, Annibale B, Lahner E. Autoimmune Gastritis and Gastric Microbiota. Microorganisms 2020;8:1827. doi:10.3390/microorganisms8111827
43 Holokai L, Chakrabarti J, Broda T, et al. Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection. PLoS Pathog 2019;15. doi:10.1371/journal.ppat.1007468
44 Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol Off J Eur Soc Med Oncol 2020;31:525–31. doi:10.1016/j.annonc.2020.01.006
45 Hakozaki T, Okuma Y, Omori M, et al. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett 2019;17:2946–52. doi:10.3892/ol.2019.9899